The GeparQuattro trial did focus on a neoadjuvant cohort using the CellSearchTM system and found prognostic ability in pre-treatment CTC counts for HER2 positive and triple negative patients using a cut-off of 2 CTCs but similar to our findings this prognostic ability was independent of the primary tumour response [25]. This evidence concerns the gene ERBB2 and neoplasm.